FN1 and chronic myelogenous leukemia, BCR-ABL1 positive: In this work, we applied this method to study the interaction of CML-derived cell lines with fibronectin and the effects of the most commonly used tyrosine kinase inhibitors, imatinib (mainly targeting BCR-ABL) and dasatinib (a dual ABL/SRC family kinase inhibitor).